tauroursodeoxycholic acid (TUDCA)

DRUG3 trials

Sponsors

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Robin Goland, MD, Fudan University

Conditions

Amyotrophic Lateral SclerosisHepatocellular Carcinoma (HCC)Type 1 Diabetes

Phase 2

Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis

CompletedNCT00877604

Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaAmyotrophic Lateral Sclerosis

Start: 2008-06-30End: 2012-04-30Updated: 2014-11-26

Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes

CompletedNCT02218619

Robin Goland, MDType 1 Diabetes

Start: 2015-08-31End: 2019-12-31Updated: 2025-06-05

Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

RecruitingNCT07100392

Fudan UniversityHepatocellular Carcinoma (HCC)

Start: 2025-08-14End: 2028-08-01Target: 141Updated: 2025-08-17